I saw that on a 'Pharmaceutical Technology' site, but in retrospect they might just be blending the weight loss trials with a sleep apnea one to get you to buy their report :
Tirzepatide is under clinical development by Eli Lilly and Co and currently in Phase III for Obstructive Sleep Apnea. According to GlobalData, Phase III drugs for Obstructive Sleep Apnea have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tirzepatide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Ann: ResMed Announces Results for the Fourth Quarter of FY2023, page-194
-
- There are more pages in this discussion • 178 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$36.99 |
Change
-0.615(1.64%) |
Mkt cap ! $23.45B | |||
| Open | High | Low | Value | Volume |
| $37.36 | $37.42 | $36.98 | $19.39M | 522.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 611 | $36.98 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $36.99 | 1218 | 15 |
View Market Depth
| Last trade - 14.00pm 13/09/2024 (20 minute delay) ? |
| RMD (ASX) Chart |